About

Primary biliary cholangitis is an autoimmune liver disease where the immune system slowly destroys the liver's small bile ducts, leading to a toxic buildup of bile that can cause scarring and cirrhosis. Saroglitazar is an oral drug that works by activating two key receptors (PPAR α/γ) in liver cells, which helps regulate how the body processes fats and sugars. By improving metabolic function in the liver, this drug may help reduce the cholestasis and inflammation that drive the disease's progression.